From: Therapeutic potential of triptolide in autoimmune diseases and strategies to reduce its toxicity
Delivery system | Excipients | Administration route | Animals | Dose of triptolide | Advantages | References |
---|---|---|---|---|---|---|
Hydrogel-thickened microemulsion | Carbomer 940, isopropyl myristate, Tween 80, propylene glycol, triethanolamine, menthol and water | Transdermal administration | New Zealand rabbits | 1.2 mg/kg (acute toxicity study), 0.06–0.54 mg/kg (long-term toxicity study) | No obvious toxicities were observed in a series of toxicity tests, only mild reversible skin irritation signs were observed on the skin of animals | [134] |
Kunming mice and beagle dogs | 0.03–0.27 mg/kg | |||||
English guinea pigs | 0.006 mg/kg (3 × 3 cm2 skin) | |||||
Microemulsion-based hydrogel | Poloxamer 407, oleic acid, Gemseal 40, Labrasol, Tween 80, ethanol and water | Transdermal administration | Rabbits | 0.24 mg (3 × 3 cm2 skin) | It afforded a better sustained release profile and strong permeability with low irritation when compared to microemulsions | [135] |
Liposome hydrogel patch | Egg lecithin, cholesterol, Viscomate NP-700, glycine aluminum, polyvinylpyrrolidone K-90, glycerin, tartaric acid and water | Transdermal administration (after treated with microneedles) | Male SD rats | 1.6, 10, 20, 40Â mg/kg | It provided a more stable and long-term release of triptolide compared with intragastric administration and had significant efficacy in CIA model | [137] |
Solid lipid nanoparticles | Glyceryl monostearate, soybean phospholipid, acetone, Poloxamer 188, Tween 80 and water | Intragastrical administration | Male SD rats | 0.45Â mg/kg | SLNs had a protective effect against triptolide-induced male reproductive toxicity due to lower concentrations in testicular tissue | [140] |
Solid lipid nanoparticles | Polyoxyl 40 hydrogenated castor oil, glyceryl behenate, diethylene glycol monoethyl ether, egg lecithin and water | Intragastrical administration | Male SD rats | 1.0Â mg/kg | SLNs alleviated the irritation in rat stomach tissues induced by triptolide, which could be attributed to reduced lipid peroxidation levels and inflammation of the stomach mucosa | [110] |
Solid lipid nanoparticles | Tristearin glyceride, Poloxamine 908, soybean lecithin and water | Intragastrical administration | Male Wistar rats and male Kunming mice | 0.2, 0.4Â mg/kg | SLNs increased the anti-inflammatory activity of triptolide and reduced triptolide-induced hepatotoxicity | [141] |
Nanostructured lipid carriers | Compritol 888 ATO, Capryol 90, Tween 80, Transcutol HP, soybean oil and water | Transdermal administration | Male SD rats | 9.3Â mg/kg | NLCs could effectively penetrate into skin for alleviating knee joint swelling and inhibiting inflammatory infiltration in RA rat model. | [143] |
Lyotropic liquid crystals | Phytantriol, carbitol, vitamin E acetate and water | Transdermal administration | SD rats | 0.08Â mg/kg | Triptolide-loaded cubic and hexagonal liquid crystals presented excellent anti-arthritic effects with no obvious toxicity | [146] |
Polymeric micelles | Methoxypolyethylene glycol–poly(D,L-lactic acid)-block copolymer | Intravenous administration | Kunming mice | 0.51–1.25 mg/kg | Its acute and subacute toxicities were slighter than free triptolide owing to the sustained release characteristics and anti-lipid oxidative damage | [85] |
Wistar rats | 0.1, 0.3Â mg/kg | |||||
Polymeric vesicles | Poly-γ-glutamic acid-grafted l-phenylalanine ethylester copolymer | Intravenous administration | C57/B6 mice | 0.5 mg/kg | It increased the survival rate of mice and reduced the damage of free TP on the liver, kidney, and spleen | [147] |
Polymeric nanoparticles | Poly-γ-glutamic acid-grafted di-tert-butyl L-aspartate hydrochloride | Intravenous administration | C57BL/6 mice | 0.15 mg/kg | It could accumulate in the inflammatory joints of TNFα-Tg mice by EPR effect, with decreased death rate and toxicity at the liver and spleen induced by triptolide | [149] |
Polymeric nanoparticles | Galactosyl-dextran-retinal conjugates | Intravenous administration | Male Balb/c mice | 0.04Â mg/kg | It preferentially accumulated in the inflamed joints through active targeting in CIA mice, thus reducing systemic toxicity | [150] |